View ValuationThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsGemini Therapeutics 향후 성장Future 기준 점검 0/6핵심 정보20.9%이익 성장률34.79%EPS 성장률Biotechs 이익 성장24.7%매출 성장률n/a향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트n/a최근 향후 성장 업데이트Price Target Changed • Nov 16Price target decreased to US$1.50Down from US$2.63, the current price target is provided by 1 analyst. New target price is 6.8% below last closing price of US$1.61. The company is forecast to post a net loss per share of US$0.32 next year compared to a net loss per share of US$1.78 last year.Price Target Changed • Apr 27Price target decreased to US$1.88Down from US$2.63, the current price target is an average from 4 analysts. New target price is 23% above last closing price of US$1.53. Stock is down 87% over the past year. The company is forecast to post a net loss per share of US$0.60 next year compared to a net loss per share of US$1.78 last year.Price Target Changed • Nov 24Price target decreased to US$19.67Down from US$22.00, the current price target is an average from 3 analysts. New target price is 539% above last closing price of US$3.08. Stock is down 69% over the past year. The company is forecast to post a net loss per share of US$1.85 next year compared to a net loss per share of US$7.19 last year.모든 업데이트 보기Recent updatesPrice Target Changed • Nov 16Price target decreased to US$1.50Down from US$2.63, the current price target is provided by 1 analyst. New target price is 6.8% below last closing price of US$1.61. The company is forecast to post a net loss per share of US$0.32 next year compared to a net loss per share of US$1.78 last year.공지 • Aug 11Disc Medicine, Inc. entered into an agreement to acquire Gemini Therapeutics, Inc. (NasdaqGM:GMTX) in a reverse merger transaction.Disc Medicine, Inc. entered into an agreement to acquire Gemini Therapeutics, Inc. (NasdaqGM:GMTX) in a reverse merger transaction on August 9, 2022. Under the terms of the all stock transaction, based on the exchange ratio, pre-merger Gemini shareholders will own approximately 28% of the combined company and pre-merger Disc stockholders will own approximately 72% of the combined company. The percentage of the combined company that Gemini’s shareholders will own as of the close of the transaction is subject to adjustment based on the amount of Gemini’s net cash at the closing date. In support of the merger, Disc has secured commitments from a syndicate of healthcare investors led by Access Biotechnology and including OrbiMed, Atlas Venture, 5AM Ventures, Novo Holdings A/S, Arix Bioscience, Rock Springs Capital, and Janus Henderson Investors, for a $53.5 million financing that is expected to close concurrent with the completion of the merger. Upon closing of the transaction, the combined company is expected to operate under the name Disc Medicine, Inc. and trade on the Nasdaq Global Market under the ticker symbol IRON. Disc will pay a termination fee of $7.8 million to Gemini, in case Disc terminates the transaction. Gemini will pay a termination fee of $3 million to Disc, in case Gemini terminates the transaction. Following the merger, the combined company will be led by John Quisel, the current Chief Executive Officer and President of Disc Medicine, and other members of the Disc management team. The Board of Directors of the combined company will be composed of nine members, including eight Disc board members and one from Gemini. Georges Gemayal, Chair of the Board and Interim Chief Executive Officer of Gemini, will be continuing as a Director of the combined company. Gemini Therapeutics, Inc. will be renamed “Disc Medicine, Inc.” and the corporate headquarters will be located in Watertown, MA. The transaction has been unanimously approved by the Board of Directors of both companies. The transaction is subject to approvals by the stockholders of both companies; Nasdaq’s approval of the listing of the shares of Gemini common stock to be issued in connection with the merger; effectiveness of the Registration Statement; and other customary closing conditions. Certain stockholders of Disc holding approximately 90% of the outstanding shares of Disc and certain stockholders of Gemini holding approximately 36% of the outstanding shares of Gemini have entered into support agreements to vote in favor of the transaction. The transaction is expected to close in the fourth quarter of 2022. Stuart M. Falber and Christopher D. Barnstable-Brown of Wilmer Cutler Pickering Hale and Dorr LLP acted as legal advisor; and SVB Securities acted as financial advisor to Gemini Therapeutics. William D. Collins of Goodwin Procter LLP acted as legal advisor; and, Morgan Stanley and Wedbush PacGrow acted as financial advisor to Disc Medicine.공지 • Jun 26+ 2 more updatesGemini Therapeutics, Inc.(NasdaqGM:GMTX) dropped from Russell 2500 Value IndexGemini Therapeutics, Inc.(NasdaqGM:GMTX) dropped from Russell 2500 Value IndexPrice Target Changed • Apr 27Price target decreased to US$1.88Down from US$2.63, the current price target is an average from 4 analysts. New target price is 23% above last closing price of US$1.53. Stock is down 87% over the past year. The company is forecast to post a net loss per share of US$0.60 next year compared to a net loss per share of US$1.78 last year.공지 • Apr 06Gemini Therapeutics, Inc. Announces Departure of Samuel Barone as Chief Medical OfficerEffective as of April 15, 2022 (the Separation Date), Samuel Barone, M.D. will depart as the Chief Medical Officer of Gemini Therapeutics, Inc.공지 • Mar 02Gemini Therapeutics, Inc. Announces Executive ChangesGemini Therapeutics, Inc. announced a leadership transition, strategic evaluation and corporate restructuring. The Board of Directors has appointed Georges Gemayel, Ph.D., the Company’s current Executive Chair, as Chief Executive Officer to succeed Jason Meyenburg, who has transitioned from his roles as President, CEO and Director and will continue to serve as an advisor to the Company.공지 • Mar 01Gemini Therapeutics, Inc. Announces Management ChangesGemini Therapeutics, Inc. announced a leadership transition, strategic evaluation and corporate restructuring. The Board of Directors has appointed Georges Gemayel, Ph.D., the Company’s current Executive Chair, as interim President to succeed Jason Meyenburg, who has transitioned from his roles as President, CEO and Director and will continue to serve as an advisor to the Company.공지 • Jan 12Gemini Therapeutics, Inc. Announces Updates from Ongoing Phase 2A Clinical Studies of GEM103 and Strategic Evaluation of GEM103's Clinical Development ProgramGemini Therapeutics, Inc. announced updates from its ongoing phase 2a clinical studies of GEM103 and strategic evaluation of GEM103’s clinical development program. GEM103 Phase 2a ReGAtta Study Update: Ongoing analysis of the 62 patients enrolled in the ReGAtta study continues to show that more than nine months of GEM103 exposure has been generally well-tolerated, able to durably reduce biomarkers of complement activation, and able to maintain supraphysiological levels of Complement Factor H (CFH). ReGAtta, an open-label, non-controlled study, was designed to evaluate GEM103’s safety and pharmacokinetics (PK) over multiple intravitreal injections. GEM103 Phase 2a as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMD Study Update: In December 2021, the Company received six-month data for the 50 patients enrolled in the wet AMD study. This study was designed to investigate the safety and tolerability of GEM103 as an adjunct to standard of care aflibercept therapy, with patients randomized 2:1 between a GEM103 plus aflibercept arm and a sham comparator plus aflibercept arm. Interim analysis showed that intravitreal GEM103 plus aflibercept was generally well-tolerated, and the safety profile was generally consistent with the sham plus aflibercept arm. Patients in this study were dosed every other month concurrently with aflibercept. CFH levels remained supraphysiologic and greater than five times above baseline at the trough timepoints throughout the six months. GEM103 Study Plans: Having achieved the ReGAtta study’s primary goal of assessing GEM103’s safety and tolerability, as well as the primary goal of assessing GEM103’s safety and tolerability as an add-on to aflibercept for the treatment of wet AMD, the Company will end both of these ongoing Phase 2a studies with patients returning for a final safety visit.Price Target Changed • Nov 24Price target decreased to US$19.67Down from US$22.00, the current price target is an average from 3 analysts. New target price is 539% above last closing price of US$3.08. Stock is down 69% over the past year. The company is forecast to post a net loss per share of US$1.85 next year compared to a net loss per share of US$7.19 last year.Executive Departure • Sep 23Chief Technology Officer Scott Lauder has left the companyOn the 17th of September, Scott Lauder's tenure as Chief Technology Officer ended after 3.9 years in the role. As of June 2021, Scott still personally held 169.23k shares (US$1.1m worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model.공지 • Jun 24Gemini Therapeutics Announces Initial Data from Its Ongoing Phase 2A Study of GEM103Gemini Therapeutics, Inc. announced initial data from its Phase 2a ReGAtta study of GEM103 as of May 2021 in patients with geographic atrophy secondary to dry AMD. ReGAtta is a dose escalation trial of GEM103, which is intravitreally administered recombinant human complement factor H (CFH), in dry AMD patients. The trial, which remains ongoing, is designed to evaluate safety and tolerability, as well as measures of intraocular pharmacokinetics (PK) and disease-relevant biomarkers, to inform the late-stage development program. ReGAtta was designed to evaluate repeat dosing of GEM103 and assess its safety in an open-label study that enrolled 62 patients with GA secondary to dry AMD. The first 36 patients enrolled received monthly 250µg intravitreally administered doses of GEM103. After evaluating the safety profile of repeated dosing over three months, patients were dose escalated to 500µg and an additional 26 patients enrolled and received monthly 500µg doses. After completing the first six months of dosing, each patient will have the option to continue receiving GEM103 for up to an additional 12 months. Patients enrolled in ReGAtta had a mean age of 78 and GA secondary to dry AMD in the study eye with 63% of patients also having GA in the fellow eye. Choroidal neovascularization in the study eye was an exclusion criterion, however 30% of patients had a history of CNV in the fellow eye at baseline. Among the baseline characteristics in the study eye, mean best corrected visual acuity (BCVA) score, as measured by Early Treatment Diabetic Retinopathy Study (ETDRS) letters, at enrollment was 61.5 (with a range of 14-86). Average GA size was 8.1 mm2. The GA was foveal in 68% of patients and multifocal in 63% of patients. Loss of function variants in the CFH gene were confirmed in 55 of the 62 patients enrolled. A total of 43 patients carry a homozygous AMD risk variation at the 402 locus of the CFH gene and six patients carry a rare heterozygous variant in CFH. Summarized results observed to date in the ongoing Phase 2a ReGAtta study include the following: Demonstration of Biological Activity, Complement Regulation and Dosing Frequency Intraocular measures of CFH and biomarkers demonstrated GEM103’s biological activity to regulate complement and support every other month dosing. Both 250µg and 500µg doses of GEM103 resulted in sustained, elevated CFH levels from the first evaluated time point of one month (at least 6-fold and 12-fold above baseline, respectively) that continued to increase dose dependently; Changes in biomarkers of complement activation indicated that GEM103 has the ability to regulate the complement system and overall disease-related inflammation, with an ~40% reduction in Ba, ~20% reduction in C3a and an increase in CFB, consistent across all genotypes. GEM103 Continued to be Well-tolerated with a Differentiated Safety Profile: GEM103 was well-tolerated with no serious adverse events related to study drug and no serious ocular adverse events as of May. There were no early discontinuations due to the study drug; Over 390 injections of GEM103 were administered, which equates to a total of 28 patient-years of exposure. Treatment was well-tolerated with only 16 patients (26%) experiencing adverse events in the study eye. Among these events, 12 patients’ adverse events were related to the intravitreal administration procedure with conjunctival hemorrhage as the most common reported adverse event; Active monitoring was conducted for retina-specific safety including inflammation and CNV. Dilated retina exams were conducted at every study visit and retinal imaging was performed every three months. An independent reading center reviewed such data; There were no endophthalmitis and no vitritis, retinal vasculitis or vascular occlusive events. Mild iritis (< 1+ cell) was observed in the study eye in three patients (4.8%); all cases resolved with either observation only or topical therapy. One case was reported as related to GEM103, and all patients continued on study without disruption of GEM103 dosing schedule; One case of CNV in a study eye presented as a macular hemorrhage at month 1 in the 500µg cohort was determined by the investigator not to be related to GEM103 or the intravitreal administration procedure. The patient is receiving anti-VEGF treatment and has continued on study; There were no cases of CNV confirmed in the study eye by the independent reading center’s analysis of the retinal imaging. Visual acuity remained stable (±5 EDTRS letters) throughout the study; GA progression at three months and six months in the study eye compared to fellow eyes that also meet the inclusion criteria was statistically indistinguishable.Recent Insider Transactions • May 19CEO, President & Director recently bought US$123k worth of stockOn the 14th of May, Jason Meyenburg bought around 13k shares on-market at roughly US$9.46 per share. This was the largest purchase by an insider in the last 3 months. This was Jason's only on-market trade for the last 12 months.공지 • May 14Gemini Therapeutics Completes Enrollment in Phase 2a Study of Gem103 as an Add-On to anti-VEGF Therapy for the Treatment of Wet Amd Patients at Risk for Progressive Vision Loss Due to Macular AtrophyGemini Therapeutics, Inc. announced the completion of enrollment in its Phase 2a trial advancing GEM103 as a potential add-on therapy for patients suffering from wet AMD and requiring continued anti-vascular endothelial growth factor (anti-VEGF) treatment who have, or may be at risk for, macular atrophy (MA). Topline data related to safety, tolerability, effect on intraocular complement factor H (CFH) levels and disease-relevant biomarkers of complement regulation is expected in late 2021. The ongoing Phase 2a, multicenter, multiple-dose study in subjects with Neovascular Age-related Macular Degeneration (nAMD) with or at risk for macular atrophy, is designed to investigate the safety and tolerability of GEM103 as an adjunct to standard of care aflibercept therapy. The study is designed to enroll approximately 45 patients randomized 2:1 between GEM103 plus aflibercept and sham plus aflibercept arms, with treatment administered via intravitreal injection every other month for twelve months. CFH levels and disease relevant biomarkers of complement regulation are determined from aqueous humor sampling throughout the study with visual acuity and macular atrophy size measured at defined dosing dates.Executive Departure • Apr 18Chief Medical Officer has left the companyOn the 12th of April, Marc Uknis' tenure as Chief Medical Officer ended after 1.1 years in the role. We don't have any record of a personal shareholding under Marc's name. Marc is the only executive to leave the company over the last 12 months.공지 • Feb 25Gemini Therapeutics, Inc. Appoints Brian Piekos Principal Financial OfficerThe Board of Directors of Gemini Therapeutics, Inc. (f/k/a FS Development Corp.) appointed Brian Piekos, the Company's Chief Financial Officer, as principal accounting officer and principal financial officer of the Company, effective February 17, 2021. Mr. Piekos will assume responsibility as principal accounting officer and principal financial officer from Gregg Beloff. Mr. Piekos joined the Company from AMAG Pharmaceuticals, where he was most recently Executive Vice President, Chief Financial Officer and Treasurer.공지 • Feb 11Gemini Therapeutics Completes Enrollment in Phase 2a Trial of GEM103 in Dry Age-Related Macular Degeneration in Patients with High-Risk Genetic VariantsGemini Therapeutics Inc. announced the completion of enrollment in its Phase 2a “ReGAtta” study. ReGAtta is a dose escalation trial of GEM103, a recombinant human complement factor H (CFH), in dry AMD patients with CFH loss-of-function gene variants. The trial is designed to evaluate safety and tolerability as well as measures of intraocular pharmacokinetics (PK) and disease-relevant biomarkers to inform the late-stage development program. The ongoing Phase 2a, multi-center, open-label, multiple ascending dose study of GEM103 in genetically-defined patients with GA secondary to dry AMD is designed to investigate safety and tolerability, PK, exploratory ocular biomarkers, and measures of retinal anatomy and function. GEM103 is delivered monthly by an intravitreal injection and PK and biomarkers of complement regulation are determined from aqueous humor sampling. The study was designed to enroll approximately 60 patients with gene variants that have been linked to the progression of dry AMD from early to late-stage.공지 • Feb 10FS Development Corp. Appoints Brian Piekos as Chief Financial OfficerFS Development Corp. announced that Brian Piekos has been appointed to serve as Chief Financial Officer. Mr. Piekos brings more than 20 years of experience in industry and finance to Gemini. Mr. Piekos joins Gemini from AMAG Pharmaceuticals, where he was most recently Executive Vice President, Chief Financial Officer and Treasurer. Prior to joining AMAG, he held leadership roles in Corporate Finance, Tax and Treasury at Cubist Pharmaceuticals. Mr. Piekos began his career as a healthcare investment banker at Needham & Company and Leerink Partners, now SVB Leerink.이익 및 매출 성장 예측NasdaqGM:GMTX - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2024N/A-14-12N/A112/31/2023N/A-14-12N/A112/31/2022N/A-14-12N/A19/30/2022N/A-43-43-43N/A6/30/2022N/A-59-55-55N/A3/31/2022N/A-68-61-61N/A12/31/2021N/A-72-60-60N/A9/30/2021N/A-68-56-56N/A6/30/2021N/A-60-47-47N/A3/31/2021N/A-50-38-38N/A12/31/2020N/A-41-33-33N/A9/30/2020N/A-36-35-35N/A6/30/2020N/A-37-37-37N/A3/31/2020N/A-41-39-39N/A12/31/2019N/A-41-39-39N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: GMTX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: GMTX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: GMTX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: GMTX 의 수익이 US 시장보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.고성장 매출: GMTX 은(는) 내년에 수익이 없을 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: GMTX의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2022/12/30 20:41종가2022/12/29 00:00수익2022/09/30연간 수익2021/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Gemini Therapeutics, Inc.는 4명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Graig SuvannavejhGoldman SachsMatthew CaufieldH.C. Wainwright & Co.Christopher HowertonJefferies LLC1명의 분석가 더 보기
Price Target Changed • Nov 16Price target decreased to US$1.50Down from US$2.63, the current price target is provided by 1 analyst. New target price is 6.8% below last closing price of US$1.61. The company is forecast to post a net loss per share of US$0.32 next year compared to a net loss per share of US$1.78 last year.
Price Target Changed • Apr 27Price target decreased to US$1.88Down from US$2.63, the current price target is an average from 4 analysts. New target price is 23% above last closing price of US$1.53. Stock is down 87% over the past year. The company is forecast to post a net loss per share of US$0.60 next year compared to a net loss per share of US$1.78 last year.
Price Target Changed • Nov 24Price target decreased to US$19.67Down from US$22.00, the current price target is an average from 3 analysts. New target price is 539% above last closing price of US$3.08. Stock is down 69% over the past year. The company is forecast to post a net loss per share of US$1.85 next year compared to a net loss per share of US$7.19 last year.
Price Target Changed • Nov 16Price target decreased to US$1.50Down from US$2.63, the current price target is provided by 1 analyst. New target price is 6.8% below last closing price of US$1.61. The company is forecast to post a net loss per share of US$0.32 next year compared to a net loss per share of US$1.78 last year.
공지 • Aug 11Disc Medicine, Inc. entered into an agreement to acquire Gemini Therapeutics, Inc. (NasdaqGM:GMTX) in a reverse merger transaction.Disc Medicine, Inc. entered into an agreement to acquire Gemini Therapeutics, Inc. (NasdaqGM:GMTX) in a reverse merger transaction on August 9, 2022. Under the terms of the all stock transaction, based on the exchange ratio, pre-merger Gemini shareholders will own approximately 28% of the combined company and pre-merger Disc stockholders will own approximately 72% of the combined company. The percentage of the combined company that Gemini’s shareholders will own as of the close of the transaction is subject to adjustment based on the amount of Gemini’s net cash at the closing date. In support of the merger, Disc has secured commitments from a syndicate of healthcare investors led by Access Biotechnology and including OrbiMed, Atlas Venture, 5AM Ventures, Novo Holdings A/S, Arix Bioscience, Rock Springs Capital, and Janus Henderson Investors, for a $53.5 million financing that is expected to close concurrent with the completion of the merger. Upon closing of the transaction, the combined company is expected to operate under the name Disc Medicine, Inc. and trade on the Nasdaq Global Market under the ticker symbol IRON. Disc will pay a termination fee of $7.8 million to Gemini, in case Disc terminates the transaction. Gemini will pay a termination fee of $3 million to Disc, in case Gemini terminates the transaction. Following the merger, the combined company will be led by John Quisel, the current Chief Executive Officer and President of Disc Medicine, and other members of the Disc management team. The Board of Directors of the combined company will be composed of nine members, including eight Disc board members and one from Gemini. Georges Gemayal, Chair of the Board and Interim Chief Executive Officer of Gemini, will be continuing as a Director of the combined company. Gemini Therapeutics, Inc. will be renamed “Disc Medicine, Inc.” and the corporate headquarters will be located in Watertown, MA. The transaction has been unanimously approved by the Board of Directors of both companies. The transaction is subject to approvals by the stockholders of both companies; Nasdaq’s approval of the listing of the shares of Gemini common stock to be issued in connection with the merger; effectiveness of the Registration Statement; and other customary closing conditions. Certain stockholders of Disc holding approximately 90% of the outstanding shares of Disc and certain stockholders of Gemini holding approximately 36% of the outstanding shares of Gemini have entered into support agreements to vote in favor of the transaction. The transaction is expected to close in the fourth quarter of 2022. Stuart M. Falber and Christopher D. Barnstable-Brown of Wilmer Cutler Pickering Hale and Dorr LLP acted as legal advisor; and SVB Securities acted as financial advisor to Gemini Therapeutics. William D. Collins of Goodwin Procter LLP acted as legal advisor; and, Morgan Stanley and Wedbush PacGrow acted as financial advisor to Disc Medicine.
공지 • Jun 26+ 2 more updatesGemini Therapeutics, Inc.(NasdaqGM:GMTX) dropped from Russell 2500 Value IndexGemini Therapeutics, Inc.(NasdaqGM:GMTX) dropped from Russell 2500 Value Index
Price Target Changed • Apr 27Price target decreased to US$1.88Down from US$2.63, the current price target is an average from 4 analysts. New target price is 23% above last closing price of US$1.53. Stock is down 87% over the past year. The company is forecast to post a net loss per share of US$0.60 next year compared to a net loss per share of US$1.78 last year.
공지 • Apr 06Gemini Therapeutics, Inc. Announces Departure of Samuel Barone as Chief Medical OfficerEffective as of April 15, 2022 (the Separation Date), Samuel Barone, M.D. will depart as the Chief Medical Officer of Gemini Therapeutics, Inc.
공지 • Mar 02Gemini Therapeutics, Inc. Announces Executive ChangesGemini Therapeutics, Inc. announced a leadership transition, strategic evaluation and corporate restructuring. The Board of Directors has appointed Georges Gemayel, Ph.D., the Company’s current Executive Chair, as Chief Executive Officer to succeed Jason Meyenburg, who has transitioned from his roles as President, CEO and Director and will continue to serve as an advisor to the Company.
공지 • Mar 01Gemini Therapeutics, Inc. Announces Management ChangesGemini Therapeutics, Inc. announced a leadership transition, strategic evaluation and corporate restructuring. The Board of Directors has appointed Georges Gemayel, Ph.D., the Company’s current Executive Chair, as interim President to succeed Jason Meyenburg, who has transitioned from his roles as President, CEO and Director and will continue to serve as an advisor to the Company.
공지 • Jan 12Gemini Therapeutics, Inc. Announces Updates from Ongoing Phase 2A Clinical Studies of GEM103 and Strategic Evaluation of GEM103's Clinical Development ProgramGemini Therapeutics, Inc. announced updates from its ongoing phase 2a clinical studies of GEM103 and strategic evaluation of GEM103’s clinical development program. GEM103 Phase 2a ReGAtta Study Update: Ongoing analysis of the 62 patients enrolled in the ReGAtta study continues to show that more than nine months of GEM103 exposure has been generally well-tolerated, able to durably reduce biomarkers of complement activation, and able to maintain supraphysiological levels of Complement Factor H (CFH). ReGAtta, an open-label, non-controlled study, was designed to evaluate GEM103’s safety and pharmacokinetics (PK) over multiple intravitreal injections. GEM103 Phase 2a as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMD Study Update: In December 2021, the Company received six-month data for the 50 patients enrolled in the wet AMD study. This study was designed to investigate the safety and tolerability of GEM103 as an adjunct to standard of care aflibercept therapy, with patients randomized 2:1 between a GEM103 plus aflibercept arm and a sham comparator plus aflibercept arm. Interim analysis showed that intravitreal GEM103 plus aflibercept was generally well-tolerated, and the safety profile was generally consistent with the sham plus aflibercept arm. Patients in this study were dosed every other month concurrently with aflibercept. CFH levels remained supraphysiologic and greater than five times above baseline at the trough timepoints throughout the six months. GEM103 Study Plans: Having achieved the ReGAtta study’s primary goal of assessing GEM103’s safety and tolerability, as well as the primary goal of assessing GEM103’s safety and tolerability as an add-on to aflibercept for the treatment of wet AMD, the Company will end both of these ongoing Phase 2a studies with patients returning for a final safety visit.
Price Target Changed • Nov 24Price target decreased to US$19.67Down from US$22.00, the current price target is an average from 3 analysts. New target price is 539% above last closing price of US$3.08. Stock is down 69% over the past year. The company is forecast to post a net loss per share of US$1.85 next year compared to a net loss per share of US$7.19 last year.
Executive Departure • Sep 23Chief Technology Officer Scott Lauder has left the companyOn the 17th of September, Scott Lauder's tenure as Chief Technology Officer ended after 3.9 years in the role. As of June 2021, Scott still personally held 169.23k shares (US$1.1m worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model.
공지 • Jun 24Gemini Therapeutics Announces Initial Data from Its Ongoing Phase 2A Study of GEM103Gemini Therapeutics, Inc. announced initial data from its Phase 2a ReGAtta study of GEM103 as of May 2021 in patients with geographic atrophy secondary to dry AMD. ReGAtta is a dose escalation trial of GEM103, which is intravitreally administered recombinant human complement factor H (CFH), in dry AMD patients. The trial, which remains ongoing, is designed to evaluate safety and tolerability, as well as measures of intraocular pharmacokinetics (PK) and disease-relevant biomarkers, to inform the late-stage development program. ReGAtta was designed to evaluate repeat dosing of GEM103 and assess its safety in an open-label study that enrolled 62 patients with GA secondary to dry AMD. The first 36 patients enrolled received monthly 250µg intravitreally administered doses of GEM103. After evaluating the safety profile of repeated dosing over three months, patients were dose escalated to 500µg and an additional 26 patients enrolled and received monthly 500µg doses. After completing the first six months of dosing, each patient will have the option to continue receiving GEM103 for up to an additional 12 months. Patients enrolled in ReGAtta had a mean age of 78 and GA secondary to dry AMD in the study eye with 63% of patients also having GA in the fellow eye. Choroidal neovascularization in the study eye was an exclusion criterion, however 30% of patients had a history of CNV in the fellow eye at baseline. Among the baseline characteristics in the study eye, mean best corrected visual acuity (BCVA) score, as measured by Early Treatment Diabetic Retinopathy Study (ETDRS) letters, at enrollment was 61.5 (with a range of 14-86). Average GA size was 8.1 mm2. The GA was foveal in 68% of patients and multifocal in 63% of patients. Loss of function variants in the CFH gene were confirmed in 55 of the 62 patients enrolled. A total of 43 patients carry a homozygous AMD risk variation at the 402 locus of the CFH gene and six patients carry a rare heterozygous variant in CFH. Summarized results observed to date in the ongoing Phase 2a ReGAtta study include the following: Demonstration of Biological Activity, Complement Regulation and Dosing Frequency Intraocular measures of CFH and biomarkers demonstrated GEM103’s biological activity to regulate complement and support every other month dosing. Both 250µg and 500µg doses of GEM103 resulted in sustained, elevated CFH levels from the first evaluated time point of one month (at least 6-fold and 12-fold above baseline, respectively) that continued to increase dose dependently; Changes in biomarkers of complement activation indicated that GEM103 has the ability to regulate the complement system and overall disease-related inflammation, with an ~40% reduction in Ba, ~20% reduction in C3a and an increase in CFB, consistent across all genotypes. GEM103 Continued to be Well-tolerated with a Differentiated Safety Profile: GEM103 was well-tolerated with no serious adverse events related to study drug and no serious ocular adverse events as of May. There were no early discontinuations due to the study drug; Over 390 injections of GEM103 were administered, which equates to a total of 28 patient-years of exposure. Treatment was well-tolerated with only 16 patients (26%) experiencing adverse events in the study eye. Among these events, 12 patients’ adverse events were related to the intravitreal administration procedure with conjunctival hemorrhage as the most common reported adverse event; Active monitoring was conducted for retina-specific safety including inflammation and CNV. Dilated retina exams were conducted at every study visit and retinal imaging was performed every three months. An independent reading center reviewed such data; There were no endophthalmitis and no vitritis, retinal vasculitis or vascular occlusive events. Mild iritis (< 1+ cell) was observed in the study eye in three patients (4.8%); all cases resolved with either observation only or topical therapy. One case was reported as related to GEM103, and all patients continued on study without disruption of GEM103 dosing schedule; One case of CNV in a study eye presented as a macular hemorrhage at month 1 in the 500µg cohort was determined by the investigator not to be related to GEM103 or the intravitreal administration procedure. The patient is receiving anti-VEGF treatment and has continued on study; There were no cases of CNV confirmed in the study eye by the independent reading center’s analysis of the retinal imaging. Visual acuity remained stable (±5 EDTRS letters) throughout the study; GA progression at three months and six months in the study eye compared to fellow eyes that also meet the inclusion criteria was statistically indistinguishable.
Recent Insider Transactions • May 19CEO, President & Director recently bought US$123k worth of stockOn the 14th of May, Jason Meyenburg bought around 13k shares on-market at roughly US$9.46 per share. This was the largest purchase by an insider in the last 3 months. This was Jason's only on-market trade for the last 12 months.
공지 • May 14Gemini Therapeutics Completes Enrollment in Phase 2a Study of Gem103 as an Add-On to anti-VEGF Therapy for the Treatment of Wet Amd Patients at Risk for Progressive Vision Loss Due to Macular AtrophyGemini Therapeutics, Inc. announced the completion of enrollment in its Phase 2a trial advancing GEM103 as a potential add-on therapy for patients suffering from wet AMD and requiring continued anti-vascular endothelial growth factor (anti-VEGF) treatment who have, or may be at risk for, macular atrophy (MA). Topline data related to safety, tolerability, effect on intraocular complement factor H (CFH) levels and disease-relevant biomarkers of complement regulation is expected in late 2021. The ongoing Phase 2a, multicenter, multiple-dose study in subjects with Neovascular Age-related Macular Degeneration (nAMD) with or at risk for macular atrophy, is designed to investigate the safety and tolerability of GEM103 as an adjunct to standard of care aflibercept therapy. The study is designed to enroll approximately 45 patients randomized 2:1 between GEM103 plus aflibercept and sham plus aflibercept arms, with treatment administered via intravitreal injection every other month for twelve months. CFH levels and disease relevant biomarkers of complement regulation are determined from aqueous humor sampling throughout the study with visual acuity and macular atrophy size measured at defined dosing dates.
Executive Departure • Apr 18Chief Medical Officer has left the companyOn the 12th of April, Marc Uknis' tenure as Chief Medical Officer ended after 1.1 years in the role. We don't have any record of a personal shareholding under Marc's name. Marc is the only executive to leave the company over the last 12 months.
공지 • Feb 25Gemini Therapeutics, Inc. Appoints Brian Piekos Principal Financial OfficerThe Board of Directors of Gemini Therapeutics, Inc. (f/k/a FS Development Corp.) appointed Brian Piekos, the Company's Chief Financial Officer, as principal accounting officer and principal financial officer of the Company, effective February 17, 2021. Mr. Piekos will assume responsibility as principal accounting officer and principal financial officer from Gregg Beloff. Mr. Piekos joined the Company from AMAG Pharmaceuticals, where he was most recently Executive Vice President, Chief Financial Officer and Treasurer.
공지 • Feb 11Gemini Therapeutics Completes Enrollment in Phase 2a Trial of GEM103 in Dry Age-Related Macular Degeneration in Patients with High-Risk Genetic VariantsGemini Therapeutics Inc. announced the completion of enrollment in its Phase 2a “ReGAtta” study. ReGAtta is a dose escalation trial of GEM103, a recombinant human complement factor H (CFH), in dry AMD patients with CFH loss-of-function gene variants. The trial is designed to evaluate safety and tolerability as well as measures of intraocular pharmacokinetics (PK) and disease-relevant biomarkers to inform the late-stage development program. The ongoing Phase 2a, multi-center, open-label, multiple ascending dose study of GEM103 in genetically-defined patients with GA secondary to dry AMD is designed to investigate safety and tolerability, PK, exploratory ocular biomarkers, and measures of retinal anatomy and function. GEM103 is delivered monthly by an intravitreal injection and PK and biomarkers of complement regulation are determined from aqueous humor sampling. The study was designed to enroll approximately 60 patients with gene variants that have been linked to the progression of dry AMD from early to late-stage.
공지 • Feb 10FS Development Corp. Appoints Brian Piekos as Chief Financial OfficerFS Development Corp. announced that Brian Piekos has been appointed to serve as Chief Financial Officer. Mr. Piekos brings more than 20 years of experience in industry and finance to Gemini. Mr. Piekos joins Gemini from AMAG Pharmaceuticals, where he was most recently Executive Vice President, Chief Financial Officer and Treasurer. Prior to joining AMAG, he held leadership roles in Corporate Finance, Tax and Treasury at Cubist Pharmaceuticals. Mr. Piekos began his career as a healthcare investment banker at Needham & Company and Leerink Partners, now SVB Leerink.